Sarepta to tap into CRISPR treatment potential

03-11-2017

Sarepta to tap into CRISPR treatment potential

Natali_Mis / iStockphoto.com

Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).


Sarepta, CRISPR, Duchenne muscular dystrophy, licence, Duke University, CRISPR Cas9, gene editing


LSIPR